FDA grants exemption to import alert for Cellectar’s CLR 131 in pediatric patients
Cellectar announced the FDA has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization for the use of CLR 131 in connection with the company’s pediatric IND. This exemption will allow it to immediately begin enrolling patients in its Phase 1 study. March 19, 2019